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Background: The standard treatment for epithelial ovarian cancer (EOC) patients with
advanced disease is carboplatin-paclitaxel combination therapy following initial debulking
surgery, yet there is wide inter-patient variation in clinical response. We sought to identify
pharmacogenomic markers related to carboplatin-paclitaxel therapy.
Methods: The lymphoblastoid cell lines, derived from 74 invasive EOC patients seen
at the Mayo Clinic, were treated with increasing concentrations of carboplatin and/or
paclitaxel and assessed for in vitro drug response using MTT viability and caspase3/7
apoptosis assays. Drug response phenotypes IC50 (effective dose at which 50% of
cells are viable) and EC50 (dose resulting in 50% induction of caspase 3/7 activity)
were estimated for each patient to paclitaxel and carboplatin (alone and in combination).
For each of the six drug response phenotypes, a genome-wide association study was
conducted.
Results: Statistical analysis found paclitaxel in vitro drug response phenotypes to be
moderately associated with time to EOC recurrence (p = 0.008 IC50; p = 0.058 EC50).
Although no pharmacogenomic associations were significant at p < 5 × 10−8, seven
genomic loci were associated with drug response at p < 10−6, including at 4q21.21
for carboplatin, 4p16.1 and 5q23.2 for paclitaxel, and 3q24, 10q, 1q44, and 13q21 for
combination therapy. Nearby genes of interest include FRAS1, MGC32805, SNCAIP,
SLC9A9, TIAL1, ZNF731P, and PCDH20.
Conclusions: These results suggest the existence of genetic loci associated with
response to platinum-taxane therapies. Further research is needed to understand the
mechanism by which these loci may impact EOC clinical response to this commonly
used regimen.
Keywords: pharmacogenomics, genome-wide association, carboplatin, paclitaxel, ovarian cancer, cell viability,
apoptosis, lymphoblastoid cell lines
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INTRODUCTION
Epithelial ovarian cancer (EOC) is the fifth leading cause of
cancer death among women in the United States (6% of cancer
deaths); in 2015, it is estimated that 14,180 women will die
from the disease (Siegel et al., 2015). The standard treatment
for patients with advanced disease is initial debulking surgery
followed by carboplatin-paclitaxel combination chemotherapy
(Marsh, 2009). Five-year overall survival remains around 45%
(Marsh, 2009), yet there is a wide inter-patient variation in
response. Currently there are few reliable prognostic biomarkers
for the classification of patients and treatment response.
Platinating agents, such as carboplatin, interfere with DNA via
inter-strand, intra-strand, and DNA-protein crosslinks, thereby
causing DNA damage and prevention of cell division and
growth, resulting in cell-cycle arrest and apoptosis (Dekou
et al., 2001). Although platinum-based drugs are widely used
in cancer treatment, many tumors are completely resistant
to these drugs, and no clinical response is attained. Major
molecular mechanisms underlying this resistance might involve
alteration in platinum inactivation or reduced intracellular
accumulation by uptake/eﬄux transporters, increased repair
of adducts, increased adduct tolerance or failure of apoptotic
pathway. Taxane agents, such as paclitaxel, are commonly used
chemotherapeutic drugs often in combination with platinating
agents. Taxanes block cell division by binding to α-tubulin,
stabilizing the microtubules, thus resulting in cell death (Huizing
et al., 1995; Jordan and Wilson, 2004). The development of
taxane resistance is common, where response has been linked
to metabolism and disposition molecules, such as, cytochrome
P450s and drug transporters (e.g., ABCB1, ABCG2, ABCC1,
ABCC2, and SLC01B3; Hewett et al., 2002; Rodriguez-Antona,
2010). In particular, studies in colorectal cell lines and tumor
tissue have shown that CYP2C8 may play a role in paclitaxel
resistance and the CYP3A may be involved in local inactivation
of paclitaxel (Martinez et al., 2002; Garcia-Martin et al.,
2006). Additionally, CYP2C8 and CYP3A4 are high involved
in the metabolism of paclitaxel in patients with ovarian cancer
(Bergmann et al., 2011), while breast cancer patients carrying the
∗3 variant of CYP2C8 have better response to paclitaxel, but at an
increase in peripheral neurotoxicity (Hertz et al., 2012).
However, these molecules do not explain all the variation
in taxane response or resistance. Inherited variation in many
of the genes encoding these molecules have been assessed
for association with clinical outcome with inconsistent results
(Peethambaram et al., 2011; Johnatty et al., 2013; White et al.,
2013); genome-wide searches to date have also failed to identify
variants associated with outcome after correction for genome-
wide testing (p< 5× 10−8). Patient-derived cell line basedmodel
systems represent a novel way to identify genomic predictors
of drug response. Although lymphoblastoid cell lines (LCLs)
derived from participants in the international HapMap project
have been used to identify genomic predictors of cytotoxic effects
of various chemotherapeutic agents (Li et al., 2008, 2010; Niu
et al., 2010; Huang et al., 2011;Wu et al., 2011), they are limited as
they are not derived from the EOC population but from healthy
individuals.
In this study, we generated LCLs derived from Mayo
Clinic EOC patients, conducted in vitro cytotoxic studies, and
associated in vitro drug response phenotypes with germline
genotype. Utilizing patient-derived LCLs, as opposed to
commercially available LCLs, allows us to screen and directly
correlate in vitro phenotypes and clinical responses. These
genome-wide association scans (GWAS) should contribute to
the identification of predictive markers of treatment responses
and ultimately improve clinicians’ ability to tailor therapy
decisions for EOC patients.
MATERIALS AND METHODS
Patients, Lymphoblastoid Cell Lines, and
Cytotoxicity Assays
Prior to initiation of chemotherapy, ovarian cancer patients
diagnosed at the Mayo Clinic between 2000 and 2003 provided
blood for immediate germline DNA extraction and for the
creation of Epstein Barr Virus (EBV)-transformed LCLs. Samples
from 74 patients were successfully transformed and subjected
to in vitro drug testing. All patients provided informed written
consent, including for passive and active follow-up, using
protocols approved by the appropriate Institutional Review
Board at the Mayo Clinic in Rochester, MN.
In vitro cellular chemo-sensitivity studies of LCLs were
performed in two batches (N = 33, N = 41) using identical
procedures and assays. Cells were maintained in RPMI1640
media supplemented with 2 mM L-glutamine, and 15% fetal
bovine serum at 37◦C under 5% CO2. Following 24 h
incubation, LCLs were treated with increasing concentrations of
carboplatin and/or paclitaxel (in duplicate). The concentrations
of carboplatin were 0, 5, 10, 20, 40, 80, and 128 µM, while for
paclitaxel were 0, 4.5, 7.5, 10, 20, 40, and 80 nM when used
as single agents. In drug combination experiments, we used
half of the doses for each drug in increasing doses (i.e., 2.5
µM carboplatin + 2.25 nM paclitaxel for “dose level 1” and
so on). Cell viability 48 h post-treatment was determined using
standard MTT assay (Li et al., 2008; Gamazon et al., 2010).
Caspase3/7 (Promega) apoptosis assays were performed at the
same time in parallel plates. A Synergy 3 plate reader (BioTek
Instruments) was used to read absorbance (cell viability using
MTT) or fluorescence (for caspase3/7 activity) intensities.
Four parameter logistic dose response curves Yi = α +
(β − α) /
(
1+
[
Di
θ
]φ)
were fit to the in vitro drug response
measurements (cell survival and caspase3/7 activity assays)
for each LCL and treatment (paclitaxel, carboplatin, and
combination), where Yi is the measurement at dose i (Di), α
α is the estimated bottom of the curve (i.e., measurement as
Di → ∞), β → ∞), β is the estimated top of the curve (i.e.,
measurement as Di → 0) , φ is the slope of the curve, and θ
is the inflection point of the curve (i.e., concentration giving a
response half way between the top and bottom of the curve).
The estimated inflection point of the curve was used as the drug
response phenotype. That is, using these dose-response curves,
we estimated the relative IC50 (effective dose that kills 50% of the
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cells) for MTT cell viability and the relative EC50 (concentration
required to induce caspase 3/7 activity by 50%) for caspase3/7
activity. For simplicity of presentation, we will refer to these
quantitative values as the IC50 for the MTT cytotoxicity assays
and EC50 for the caspase 3/7 assays. We then applied rank-based
inverse Gaussian transformation (i.e., Van de Waerden rank
transformation). Summaries of the IC50 and EC50 values for
both experimental batches are presented in Supplemental Table
1. We observed a high degree of correlation between many of the
drug response phenotypes, as expected (Supplemental Figure 1).
Genotyping and Statistical Methods
Germline DNA was genotyped on the Illumina Infinium 610K
array, as previously described (Pharoah et al., 2013). All samples
had genotype call rate>95% andwere predicted by STRUCTURE
(Pritchard et al., 2000) analysis to have greater than 80%
European ancestry. SNPs were excluded with call rate < 95%,
Hardy-Weinberg Equilibrium p < 10−4, or no variation in this
set. Using the 1000 Genomes Project (Durbin et al., 2010) as
reference, imputation was completed with mach and minimac
in a two-step process (Howie et al., 2012), resulting in data on
more than 30 million SNPs. Assessment of imputation quality
was completed and high quality imputed markers (r2 ≥ 0.30 and
MAF ≥ 0.01) were retained (6,243,550 SNPs).
The association of each SNP with in vitro drug response
phenotypes IC50 or EC50 was evaluated with linear models
using the expected genotype or “dosage” (i.e., additive or dose-
response/trend model). Thus, a negative effect estimate indicates
that the carriers of the minor/rare allele have lower IC50 (EC50)
values (i.e., were more “sensitive” to treatment). The two in vitro
experimental batches were analyzed separately followed by meta-
analysis was conducted using metal (Willer et al., 2010), with
weights applied for the number of samples in each group. We
completed the GWAS analyses for each individual in vitro drug
response phenotype, as opposed to a combined analysis with all
phenotypes model together, due to the difference in mechanism
of action between the drugs (i.e., not in the same drug class;
Fridley et al., 2012). For annotation of results across gene regions,
SNPs were mapped to genes within 2 KB using Biofilter (assembly
CRCh37.p10, genome build 104.0; Bush et al., 2009). Pathway
analysis used Ingenuity Pathway Analysis (IPA) (Ingenuity R©
Systems, www.ingenuity.com).
RESULTS
We examined the relationships of in vitro phenotypes with
time to recurrence of EOC (40 of 74 patients had recurred or
died). Of the 74 patients with LCLs included in this study, 51
had available information on the first two treatments used: 43
patients were treated with paclitaxel / carboplatin, 2 treated with
paclitaxel/cisplatin, 3 treated with carboplatin/topotecan, and 3
treated with carboplatin/other less common agent. Paclitaxel in
vitro drug response phenotypes were moderately associated with
time to EOC recurrence (HR = 1.90 per unit increase in MTT
IC50, p = 0.008; HR = 1.84 per unit increase in caspase 3/7
EC50, p = 0.058; Figure 1; Supplemental Table 2). This suggests
that patients whose LCLs demonstrated greater sensitivity to the
chemotherapeutics tested had improved outcome; as Figure 1
illustrates, LCLs that were sensitive to paclitaxel (as reflected
by having low IC50 and low EC50 values) were from patients
with longer time to progression as compared to patients with
LCLs with high values. Although based on a small sample size,
this provides, for the first time, a link between in vitro chemo-
sensitivity testing and clinical outcome in EOC.
Results of genome-wide association analyses for each drug
response phenotype are presented in Figure 2. Regions with
FIGURE 1 | Kaplan-Meier curves for time to progression and paclitaxel in vitro phenotypes. The groupings were defined by 3 quartiles representing low,
medium or high values for the phenotype based (A) MTT assay IC50 or (B) Caspase 3/7 EC50 assay. The p-value presented is from a Cox proportional hazards
model with the in vitro phenotype modeled as a continuous measurement on the log-scale.
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FIGURE 2 | Manhattan plots of the single SNP meta-analysis genome-wide association results based the six in vitro drug response measures among
ovarian cancer patient LCLs. (A) Carboplatin MTT; (B) Paclitaxel MTT; (C) Combination of carboplatin and paclitaxel MTT; (D) Carboplatin Caspase3/7; (E)
Paclitaxel Caspase3/7; and (F) Combination of carboplatin and paclitaxel Caspase3/7. Blue line indicates p = 0.00001; Red line indicates p = 5 × 10−8. Highlighted
regions (circled) are displayed in Figure 3.
p < 10−6 are highlighted and are further displayed in Figure 3.
Table 1 presents the SNPs associated with the drug response
phenotype with p< 10−6. Overall, we found a greater proportion
of significant results (e.g., at p < 10−6) for the combination
therapy as compared to the single agent therapies. In particular,
we found strong SNP associations with combination therapy in
the following gene regions: SLC9A9 (MAF= 0.41, p= 6× 10−7),
TIAL1 (MAF = 0.23, p = 7.3 × 10−7), ZNF731P (MAF = 0.39,
p = 6.6 × 10−7), and PCDH20 (MAF = 0.42, p = 8.2 ×
10−7). None of these regions were found to be moderately
associated with single agent carboplatin or paclitaxel IC50
in other pharmacogenomic studies involving commercially
available LCLs (Huang et al., 2011; Niu et al., 2012).
We evaluated potential overlap of loci associated with
both phenotypes for a given drug. Only one SNP was found
to be associated with a p < 10−4 with same direction of
the effect for MTT IC50 and caspase3/7 EC50 values for
paclitaxel, carboplatin, or combination treatment. An intronic
SNP rs35067965 in COLEC12 (chromosome 18, bp 455396) was
associated with response to paclitaxel (MTT IC50 p = 2.2 ×
10−5, caspase 3/7 EC50 p = 3.8 × 10−5; Table 2). We also
examined overlap of associations at the level of genes, considering
SNPs within 20 kb. This showed consistency of IC50 and EC50
results for paclitaxel response and COLEC12 and revealed similar
IC50 and EC50 associations for carboplatin response in the gene
regions of CTIF and CDH4. As presented in Table 3, additional
regions showed joint associations with response to multiple
drugs, including variants in protein coding regions of BRE,
EML6, CTNNA2, LRP1B, EYS, NKAIN2, ANTXRL, COL13A1,
andMTCL1 (SNPs in gene regions with p< 0.0001).
Because of the suggested association between in vitro
paclitaxel MTT IC50 response and time to EOC recurrence
(Supplemental Table 2), we also examined recurrence association
with SNPs rs185229225 (intronic BOD1L1) rs35067965 (intronic
COLEC12) and rs1525599 (intronic LRP1B) which were
associated with paclitaxel MTT IC50 (Tables 1–3, respectively).
However, none of these SNPs were associated with time to
recurrence with a nominal p< 0.05 (data not shown).
DISCUSSION
In this proof of concept study, we explored use of LCLs derived
from EOC patients followed for clinical response as a model
for discovery of pharmacogenomics markers. LCLs were treated
with varying concentration of the chemotherapeutics agents
(carboplatin and paclitaxel and, uniquely, their combination)
that were used for the treatment and cellular chemo-sensitivity
was determined by measuring cell viability and activation of
caspase activity (as a marker of apoptosis) post drug treatment.
Genome-wide association studies were performed to identify
inherited markers associated with these measures of in vitro
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FIGURE 3 | Locus Zoom plots for regions with p < 10−6. Note: BOD1L1 region not presented as only one SNP in region with p < 0.001.
chemo-sensitivity (i.e., MTT IC50 and caspase 3/7 EC50 values)
and the relationships between in vitro measures and clinical
outcome was explored.
Although the sample size was small limiting the power of
the study, some of the implicated biologically interesting genes
are worthy of discussion. Pathway analysis of genes with SNPs
showing association with one of the drug response phenotypes
(at p < 10−6), both phenotypes for a given drug (at p <
10−4), or multiple drugs for any phenotype (at p < 10−4)
found enrichment in genes related to malignant solid tumor
and epithelial cancers (Supplemental Figure 2A). Among the top
canonical pathways represented by these genes were “Epithelial
Adherens Junction Signaling,” “Sertoli Cell Junction Signaling,”
and “Endometrial Cancer Signaling” (Supplemental Figure 2B).
In addition, genes such as CTNNA2 and CDH4, both
tumor suppressor genes with role in cell adhesion were
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TABLE 1 | SNPs with p < 10−6 association with a drug response phenotype.
Drug Phenotype Nearest
gene
SNP Chr Position MAF Meta-
Analysis P
Group 1 (N = 33) Group 2 (N = 41)
Estimate P Estimate P
Paclitaxel MTT IC50 BOD1L1 rs185229225 4 13609129 0.02 2.2E-07 −2.53 8.0E-03 −11.64 4.7E-06
Caspase 3/7 EC50 MGC32805/
SNCAIP*
rs3842595 5 121778606 0.14 2.6E-07 −1.37 1.7E-03 −1.34 4.1E-05
Carboplatin MTT IC50 FRAS1 rs150303591 4 79009309 0.29 5.9E-07 0.86 2.5E-03 1.02 6.3E-05
Combination MTT IC50 SLC9A9* rs201023017 3 143103669 0.41 6.0E-07 0.84 5.2E-04 0.70 3.3E-04
TIAL1 rs66696671 10 121366953 0.23 7.3E-07 −0.89 2.9E-04 −0.76 6.6E-04
Caspase 3/7 EC50 ZNF731P rs12025262 1 247356732 0.39 6.6E-07 −0.84 2.5E-04 −0.71 6.9E-04
PCDH20 rs10674174 13 61892075 0.42 8.2E-07 −0.73 5.3E-03 −0.86 3.7E-05
*Nearest gene within 2000 base pairs.
For regions with multiple SNPs with p < 10−6, the most significant SNP is presented. A negative estimate indicates that carriers of the minor allele had, on average, lower IC50 or EC50
(“sensitive”) while a positive estimate indicates that carriers of the minor allele had, on average, higher IC50 or EC50 (“resistant”).
TABLE 2 | Gene regions with SNPs associated with both phenotypes for a given drug.
Drug Gene Phenotype SNP* Chr Position P Direction†
Paclitaxel COLEC12 MTT IC50 rs35067965 18 455396 2.2E-05 − −
Caspase 3/7 EC50 rs35067965 18 455396 3.8E-05 − −
Carboplatin CTIF MTT IC50 rs8091660 18 46087936 8.9E-06 − −
Caspase 3/7 EC50 rs113867814 18 46259604 1.2E-05 − −
CDH4 MTT IC50 rs2748151 20 60133486 4.7E-05 ++
Caspase 3/7 EC50 rs113594423 20 60379048 2.4E-05 ++
*Presenting most significant SNP in the region for the giving drug/phenotype. SNP within ± 20 KB of the listed gene.
†
A negative estimate indicates that carriers of the minor/variant allele had, on average, lower IC50 or EC50 (“sensitive”) while a positive estimate indicates that carriers of the minor/variant
allele had, on average, higher IC50 or EC50 (“resistant”).
found to be associated with chemo-sensitivity in carboplatin
alone or combination treatments. SNPs in CTNNA2- catenin
(cadherin-associated protein) alpha2, a structural constituent of
cytoskeleton and cadherin binding was associated with in vitro
cytotoxicity to carboplatin alone as well as in combination with
paclitaxel. CTNNA2 has been shown to be frequently mutated
in laryngeal carcinomas with mutations predictive of poor
prognosis (Fanjul-Fernandez et al., 2013). Additionally, SNPs
within CTNNA2 have recently been implicated in breast cancer
(Haryono et al., 2015) and its role in tumor progression and
metastasis has been suggested for multiple cancers (Mcgranahan
et al., 2015). Variants in CTNNA2 have also been implicated in
schizophrenia (Mexal et al., 2008) and alcohol addiction (Song
and Zhang, 2014). CTNNA2 SNPs associated with carboplatin
and paclitaxel MTT IC50 were both intronic and present
functional relevance of these is not known. CDH4, codes for
cadherin, and has been implicated in nasopharyngeal carcinoma
(Du et al., 2011) and aberrant methylation of CDH4 promoter
has been colorectal and gastric cancer (Miotto et al., 2004). Our
results identified two intronic SNPs (rs2748151 and rs113594423)
that were associated with carboplatin resistant as measured by
cell death (IC50) and apoptosis (caspase 3/7 EC50). Variants
in PCDH20, another member of cadherin family, were also
found to be associated in vitro drug response. PCHD20 codes
for protocadherin20 and functions as a tumor suppressor by
interacting with Wnt/b-catenin signaling (Chen et al., 2015; Lv
et al., 2015).
Another gene with role in cell adhesion identified in our
study was FRAS1, which encodes for an extracellular matrix
protein and is involved in the regulation of epidermal-basement
membrane adhesion and organogenesis during development.
Inherited mutations in FRAS1, and FREM2, have been associated
with development of Fraser syndrome. FRAS1 has also been
implicated in ERK signaling and influence migration and
invasion of lung cancer cell line by influencing FAK signaling
(Zhan et al., 2014), suggesting its role in tumorigenesis and
metastasis of lung cancer. Although the genes described above are
involved cell adhesion/cell migration, the functional significance
of the intronic SNPs identified in this study is not known and
would require further investigation.
Two intronic variants within BRE were found to be associated
with caspase 3/7 levels for carboplatin and combination therapy
(indel rs5830067 and rs7572664). BRE encodes for Brain and
reproductive Organ-Expressed (TNFRSF1A modulator) and is
a component of BRCA1-A DNA damage repair complex that
recognizes Lys 62linked ubiquitinated H2A and H2Ax at DNA
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TABLE 3 | Gene regions with SNPs associated with multiple drugs for any phenotype (p < 0.0001).
Gene Drug Phenotype SNP* Chr Position P Direction†
BRE Carboplatin Caspase 3/7 EC50 rs5830067 2 28537890 1.7E-05 ++
Combination Caspase 3/7 EC50 rs7572644 2 28320033 5.8E-06 − −
EML6 Paclitaxel Caspase 3/7 EC50 rs75314082 2 55087315 7.9E-05 − −
Combination MTT IC50 rs17046344 2 55023600 4.9E-05 ++
LINC01122 Paclitaxel Caspase 3/7 EC50 rs72817940 2 58998563 6.4E-05 ++
Carboplatin Caspase 3/7 EC50 rs4233974 2 59295043 2.6E-05 − −
CTNNA2 Carboplatin MTT IC50 rs17261321 2 80197843 3.6E-05 ++
Combination MTT IC50 rs6719499 2 80193386 6.0E-05 − −
LRP1B Paclitaxel MTT IC50 rs1525599 2 141778702 8.6E-05 ++
Combination Caspase 3/7 EC50 rs13020675 2 142212928 6.2E-05 − −
EYS Paclitaxel Caspase 3/7 EC50 rs201083182 6 65736914 2.3E-06 − −
Combination Caspase 3/7 EC50 rs2064701 6 65676556 3.6E-05 ++
NKAIN2 Paclitaxel Caspase 3/7 EC50 rs550987 6 124905510 4.1E-05 − −
Combination Caspase 3/7 EC50 rs670616 6 124885773 7.8E-05 ++
C7orf65 Carboplatin Caspase 3/7 EC50 rs10230114 7 47705506 2.4E-05 ++
Combination Caspase 3/7 EC50 rs11771997 7 47712495 2.4E-05 ++
ANTXRL Paclitaxel Caspase 3/7 EC50 rs12572446 10 47665906 4.3E-05 ++
Combination Caspase 3/7 EC50 rs10906942 10 47670851 4.9E-05 ++
COL13A1 Carboplatin Caspase 3/7 EC50 rs10999018 10 71654602 2.4E-05 ++
Combination Caspase 3/7 EC50 rs77535242 10 71652985 3.5E-05 ++
TMEM132D Paclitaxel Caspase 3/7 EC50 rs77438645 12 130304313 − − − −
Carboplatin Caspase 3/7 EC50 rs1451904 12 130166947 6.5E-05 ++
MTCL1 Carboplatin Caspase 3/7 EC50 rs690089 18 8845223 7.8E-05 − −
Combination Caspase 3/7 EC50 rs35765215 18 8839469 6.0E-05 − −
*Presenting most significant SNP in the region for the giving drug/phenotype. SNP within ± 20 KB of the listed gene.
†
A negative estimate indicates that carriers of the minor/variant allele had, on average, lower IC50 or EC50 (“sensitive”) while a positive estimate indicates that carriers of the minor/variant
allele had, on average, higher IC50 or EC50 (“resistant”).
lesions, resulting in recruitment of BRCA1-BARD1 to double
strand DNA breaks (Li et al., 1995). BRE expression has been
shown to be predictive of disease free survival in non-familial
breast cancer patients (Noordermeer et al., 2012) and recent
studies show its involvement in both intrinsic and extrinsic
apoptotic pathways by influencing XIAP (Chui et al., 2014).
Variation within EML6, which is involved assembly dynamics
of microtubules, was found to be associated with platinum-
sensitivity which was of interest since paclitaxel’s mechanism
of action involved disruption of microtubules; however no
evidence exists in the literature on functional relevance of
these particular SNPs within EML6. No other genes involved
in microtubule protein were identified with respect to paclitaxel
chemo-sensitivity.
Lastly, two intronic variants within LRP1B (low density
lipoprotein related protein 1B) were associated with paclitaxel
and combination therapy drug response phenotypes. LRP1B is a
tumor suppressor with decreased expression in several primary
cancers and is among 10 most significantly deleted genes across
3312 cancer samples (Langbein et al., 2002; Sonoda et al., 2004;
Nakagawa et al., 2006; Prazeres et al., 2011). In renal cell cancer,
down-regulation of LRP1B has been shown to regulate cell
motility and actin cytoskeleton reorganization (Lu et al., 2013).
Germline SNPs/ haplotype in LRP1B have been associated with
aging without cognitive decline (Poduslo et al., 2010); however,
associations of germline SNPs with incidence/progression of
cancer and pharmacogenomics have yet to be reported.
In summary, using a patient-derived cell-based model system
to generate several in vitro drug response phenotypes on a
clinically followed set of EOC cases we have identified genetic
loci associated with response to platinum-taxane therapies.
Overall our results identified germ-line SNPs in multiple
cell adhesion molecules and several tumor suppressor genes
(PCDH20, LRP1B, CDH4, and CTNNA2). However, none of the
most associated SNPs were reported by Huang et al. (2011)
or associated with mRNA gene expression in lymphoblastoid
cell lines (http://www.ncbi.nlm.nih.gov/projects/gap/eqtl/index.
cgi). Further studies are needed to determine if these SNPs
are truly associated with drug response or if they represent
false-positive findings. Similar to other studies comparing in
vitro chemo-sensitivity with clinical outcomes (Huang et al.,
2011; Gamazon et al., 2013), our findings suggest that in vitro
response to paclitaxel correlates with time to disease recurrence
indicating that this model may have utility in several types
of future studies. On possible explanation for the observation
that paclitaxel correlates with recurrence and not carboplatin
may be the fact that the majority of EOC patients eventually
develop platinum resistant tumors and the main factor related to
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future response maybe attributed to response to taxane therapy.
Further research is needed to understand the mechanism by
which genomic loci impact clinical response in ovarian cancer
patients to the most common regimen used in the treatment of
ovarian cancer following surgery.
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